Sidoti Research Analysts Boost Earnings Estimates for HBIO

Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) – Equities research analysts at Sidoti upped their FY2026 earnings per share estimates for Harvard Bioscience in a research note issued on Wednesday, November 11th. Sidoti analyst J. Sidoti now forecasts that the medical instruments supplier will post earnings per share of ($2.37) for the year, up from their previous forecast of ($2.44). The consensus estimate for Harvard Bioscience’s current full-year earnings is ($2.37) per share.

Harvard Bioscience (NASDAQ:HBIO – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.27. The firm had revenue of $22.20 million during the quarter, compared to analyst estimates of $21.80 million. Harvard Bioscience had a negative net margin of 13.20% and a negative return on equity of 43.94%.

HBIO has been the subject of several other research reports. Weiss Ratings raised Harvard Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, November 9th. Zacks Research started coverage on shares of Harvard Bioscience in a research report on Tuesday, November 3rd. They issued a “hold” rating on the stock. Benchmark lifted their target price on Harvard Bioscience from $6.00 to $7.50 and gave the stock a “speculative buy” rating in a research report on Wednesday, August 12th. Stonex Financial lowered shares of Harvard Bioscience from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, November 11th. Finally, StoneX cut Harvard Bioscience from a “speculative buy” rating to a “hold” rating in a report on Wednesday, November 11th. One analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $6.75.

Get Our Latest Stock Analysis on HBIO

Harvard Bioscience Trading Down 0.2%

Shares of HBIO stock opened at $8.66 on Friday. The business has a fifty day simple moving average of $8.43 and a 200-day simple moving average of $6.68. The stock has a market cap of $39.58 million, a P/E ratio of -3.34 and a beta of 1.47. The company has a quick ratio of 0.86, a current ratio of 1.76 and a debt-to-equity ratio of 7.28. Harvard Bioscience has a fifty-two week low of $4.00 and a fifty-two week high of $10.20.

Institutional Trading of Harvard Bioscience

An institutional investor recently bought a new stake in Harvard Bioscience stock. Citadel Advisors LLC bought a new position in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 13,251 shares of the medical instruments supplier’s stock, valued at approximately $81,000. Citadel Advisors LLC owned 0.29% of Harvard Bioscience at the end of the most recent reporting period. 80.87% of the stock is currently owned by institutional investors.

Harvard Bioscience Company Profile

(Get Free Report)

Harvard Bioscience, Inc. develops, manufactures and sells scientific instruments and equipment used in life science research. Its products support work in areas such as physiology, electrophysiology and preclinical research, and are used by academic and government institutions, biotechnology and pharmaceutical companies, and contract research organizations. The company’s offerings include laboratory instruments, equipment and related consumables, including systems for measuring biological activity and studying tissues, organs and cells.

Featured Articles

Earnings History and Estimates for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.